| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Vitexin 4"-O-glucoside targets multiple pathways including antioxidant defense systems, inflammatory pathways, and neuroprotective signaling. It exerts antioxidant effects by scavenging free radicals and upregulating antioxidant enzyme activity. Its anti-inflammatory activity is mediated through inhibition of pro-inflammatory cytokine production and modulation of NF-κB signaling. The compound also shows neuroprotective effects by reducing oxidative stress and inflammation in neuronal cells.
|
|---|---|
| ln Vitro |
In vitro, vitexin 4"-O-glucoside demonstrates antioxidant activity by scavenging free radicals and reducing oxidative stress in cell-based assays. It shows anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. The compound exhibits neuroprotective effects by protecting neuronal cells from oxidative stress-induced damage. Specific EC₅₀/IC₅₀ values for these activities are documented in the literature. It is soluble in DMSO and other organic solvents.
|
| ln Vivo |
In vivo, vitexin 4"-O-glucoside has been studied in animal models of oxidative stress, inflammation, and neurodegenerative disorders. It shows antioxidant and anti-inflammatory effects in various disease models. The compound's neuroprotective activity has been demonstrated in models of cerebral ischemia, Alzheimer's disease, and Parkinson's disease. Further studies are needed to fully characterize its therapeutic potential and safety profile.
|
| Enzyme Assay |
Antioxidant activity is assessed using cell-free assays such as DPPH radical scavenging, ABTS radical scavenging, and ferric reducing antioxidant power (FRAP) assays. Vitexin 4"-O-glucoside is tested at various concentrations, and IC₅₀ values are calculated. Enzyme inhibition assays may be performed to assess inhibition of enzymes such as xanthine oxidase or lipoxygenase. Anti-inflammatory activity is assessed by measuring inhibition of inflammatory mediator production in activated immune cells.
|
| Cell Assay |
In vitro cellular assays use various cell lines including neuronal cells (e.g., SH-SY5Y, PC12), immune cells (macrophages, microglia), and other cell types. Cells are treated with vitexin 4"-O-glucoside at various concentrations. Antioxidant activity is assessed by measuring ROS levels using fluorescent probes. Anti-inflammatory activity is measured by cytokine production (ELISA) and NF-κB activation. Neuroprotective effects are assessed by measuring cell viability (MTT assay) and apoptosis markers in cells exposed to oxidative stress or neurotoxic agents.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of oxidative stress, inflammation, and neurodegenerative disorders. Vitexin 4"-O-glucoside is administered orally or intraperitoneally. Endpoints include oxidative stress markers (MDA, SOD, GSH), inflammatory markers (cytokine levels, COX-2, iNOS), behavioral assessments (in models of neurodegenerative diseases), and histopathological analysis of tissues. Pharmacokinetic studies are conducted to determine plasma concentrations and tissue distribution.
|
| ADME/Pharmacokinetics |
Vitexin 4"-O-glucoside is a flavonoid glycoside. Specific chemical properties including molecular weight, molecular formula, and CAS number are documented in the literature. The compound is typically stored at -20°C and protected from light. It is soluble in DMSO and other organic solvents. Specific pharmacokinetic parameters are documented in the literature from preclinical studies. As a glycoside, it may undergo deglycosylation in the gastrointestinal tract or liver before absorption.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for vitexin 4"-O-glucoside are documented in preclinical studies. The compound is generally well-tolerated at therapeutic doses based on its natural occurrence in foods and medicinal plants. No significant toxicity has been reported at doses used in research studies. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only and not for human therapeutic applications.
|
| References | |
| Additional Infomation |
Vitexin glucoside belongs to the flavonoid class of compounds and is a C-glycoside compound.
Vitexin 4"-O-glucoside is a flavonoid glycoside with antioxidant, anti-inflammatory, and neuroprotective activities. It is found in various medicinal plants and has been studied for its potential in the treatment of oxidative stress-related diseases, inflammatory conditions, and neurodegenerative disorders. The compound's antioxidant and anti-inflammatory properties make it a promising candidate for further research in the fields of neuroprotection and natural product pharmacology. It is commercially available as a research compound and reference standard. |
| Molecular Formula |
C33H40O19
|
|---|---|
| Molecular Weight |
740.66
|
| Exact Mass |
594.158
|
| Elemental Analysis |
C, 53.51; H, 5.44; O, 41.04
|
| CAS # |
178468-00-3
|
| PubChem CID |
56776173
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
-1.9
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
42
|
| Complexity |
971
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O([C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)O)[C@@H]1[C@@H](CO)O[C@@H](C2C(=CC(=C3C(C=C(C4C=CC(=CC=4)O)OC=23)=O)O)O)[C@@H]([C@H]1O)O
|
| InChi Key |
NDSUKTASTPEKBX-LXXMDOISSA-N
|
| InChi Code |
InChI=1S/C27H30O15/c28-7-15-19(34)20(35)23(38)27(41-15)42-24-16(8-29)40-26(22(37)21(24)36)18-12(32)5-11(31)17-13(33)6-14(39-25(17)18)9-1-3-10(30)4-2-9/h1-6,15-16,19-24,26-32,34-38H,7-8H2/t15-,16-,19-,20+,21-,22-,23-,24-,26+,27+/m1/s1
|
| Chemical Name |
8-[(2S,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
|
| Synonyms |
Vitexin 4" O glucoside; Vitexin 4"-O-glucoside; Vitexin 4" O-glucoside
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~168.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3501 mL | 6.7507 mL | 13.5015 mL | |
| 5 mM | 0.2700 mL | 1.3501 mL | 2.7003 mL | |
| 10 mM | 0.1350 mL | 0.6751 mL | 1.3501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
